Proton beam therapy for hepatocellular carcinoma

References

• Torre LA, Siegel RL, Ward EM, et al. Global cancer incidence and mortality rates and trends–an update. Cancer Epidemiol Biomarkers Prev. 2016;25:16–27.
   PubMed Web of Science ®Google Scholar
• Cancer Facts & Figures 2017. American Cancer Society, 2017. [Last accessed 2017 Apr 2. Available at: https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2017.html
   Google Scholar
• Bruix J, Sherman M. American Association for the Study of Liver D. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020–1022.
   PubMed Web of Science ®Google Scholar
• European Association For The Study Of The L, European Organisation For R, Treatment Of C. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908–943.
   PubMed Web of Science ®Google Scholar
• Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693–699.
   PubMed Web of Science ®Google Scholar
• Xu Q, Kobayashi S, Ye X, et al. Comparison of hepatic resection and radiofrequency ablation for small hepatocellular carcinoma: a meta-analysis of 16,103 patients. Sci Rep. 2014;4:7252.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359:1734–1739.
   PubMed Web of Science ®Google Scholar
• Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002;35:1164–1171.
   PubMed Web of Science ®Google Scholar
• Kalogeridi MA, Zygogianni A, Kyrgias G, et al. Role of radiotherapy in the management of hepatocellular carcinoma: a systematic review. World J Hepatol. 2015;7:101–112.
   PubMedGoogle Scholar
• Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–390.
   PubMed Web of Science ®Google Scholar
• Kallini JR, Gabr A, Salem R, et al. Transarterial radioembolization with yttrium-90 for the treatment of hepatocellular carcinoma. Adv Ther. 2016;33:699–714.
   PubMed Web of Science ®Google Scholar
• Lewandowski RJ, Kulik LM, Riaz A, et al. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant. 2009;9:1920–1928.
   PubMed Web of Science ®Google Scholar
• Lawrence TS, Robertson JM, Anscher MS, et al. Hepatic toxicity resulting from cancer treatment. Int J Radiat Oncol Biol Phys. 1995;31:1237–1248.
   PubMed Web of Science ®Google Scholar
• NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Hepatobiliary Cancers (version 1.2017). National comprehensive cancer network, 2017. [Last accessed 2017 Apr 2 Available at: https://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site
   Google Scholar
• ASTRO Model Policies: Proton Beam Therapy (PBT), 2014. Last accessed 2017 Apr 23. Available at: https://www.astro.org/News-and-Publications/News-and-Media-Center/News-Releases/2014/Proton-Beam-Therapy-Model-Policy-issued-by-ASTRO/
   Google Scholar
• Korean Liver Cancer Study G, National Cancer Center K. Korean liver cancer study group-national cancer center Korea practice guideline for the management of hepatocellular carcinoma. Korean J Radiol. 2014;2015(16):465–522.
   Google Scholar
• Ingold JA, Reed GB, Kaplan HS, et al. Radiation Hepatitis. Am J Roentgenol Radium Ther Nucl Med. 1965;93:200–208.
   PubMedGoogle Scholar
• Reed GB Jr., Cox AJ Jr. The human liver after radiation injury. A form of veno-occlusive disease. Am J Pathol. 1966;48:597–611.
   PubMed Web of Science ®Google Scholar
• Kim JH, Park JW, Kim TH, et al. Hepatitis B virus reactivation after three-dimensional conformal radiotherapy in patients with hepatitis B virus-related hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2007;69:813–819.
   PubMed Web of Science ®Google Scholar
• Dawson LA, Normolle D, Balter JM, et al. Analysis of radiation-induced liver disease using the Lyman NTCP model. Int J Radiat Oncol Biol Phys. 2002;53:810–821.
   PubMed Web of Science ®Google Scholar
• Pugh RN, Murray-Lyon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60:646–649.
   PubMed Web of Science ®Google Scholar
• Cardenes HR, Price TR, Perkins SM, et al. Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma. Clin Transl Oncol. 2010;12:218–225.
   PubMed Web of Science ®Google Scholar
• Malinchoc M, Kamath PS, Gordon FD, et al. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology. 2000;31:864–871.
   PubMed Web of Science ®Google Scholar
• Johnson PJ, Berhane S, Kagebayashi C, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol. 2015;33:550–558.
   PubMed Web of Science ®Google Scholar
• Lasley FD, Mannina EM, Johnson CS, et al. Treatment variables related to liver toxicity in patients with hepatocellular carcinoma, Child-Pugh class A and B enrolled in a phase 1-2 trial of stereotactic body radiation therapy. Pract Radiat Oncol. 2015;5:e443–449.
   PubMed Web of Science ®Google Scholar
• Mizumoto M, Okumura T, Hashimoto T, et al. Evaluation of liver function after proton beam therapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2012;82:e529–535.
   PubMed Web of Science ®Google Scholar
• Ling TC, Kang JI, Bush DA, et al. Proton therapy for hepatocellular carcinoma. Chin J Cancer Res. 2012;24:361–367.
   PubMed Web of Science ®Google Scholar
• Gandhi SJ, Liang X, Ding X, et al. Clinical decision tool for optimal delivery of liver stereotactic body radiation therapy: photons versus protons. Pract Radiat Oncol. 2015;5:209–218.
   PubMedGoogle Scholar
• Taddei PJ, Howell RM, Krishnan S, et al. Risk of second malignant neoplasm following proton versus intensity-modulated photon radiotherapies for hepatocellular carcinoma. Phys Med Biol. 2010;55:7055–7065.
   PubMed Web of Science ®Google Scholar
• Toramatsu C, Katoh N, Shimizu S, et al. What is the appropriate size criterion for proton radiotherapy for hepatocellular carcinoma? A dosimetric comparison of spot-scanning proton therapy versus intensity-modulated radiation therapy. Radiat Oncol. 2013;8:48.
   PubMed Web of Science ®Google Scholar
• Wang X, Krishnan S, Zhang X, et al. Proton radiotherapy for liver tumors: dosimetric advantages over photon plans. Med Dosim. 2008;33:259–267.
   PubMed Web of Science ®Google Scholar
• Kim JY, Lim YK, Kim TH, et al. Normal liver sparing by proton beam therapy for hepatocellular carcinoma: comparison with helical intensity modulated radiotherapy and volumetric modulated arc therapy. Acta Oncol. 2015;54:1827–1832.
   PubMed Web of Science ®Google Scholar
• Ben-Josef E, Normolle D, Ensminger WD, et al. Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies. J Clin Oncol. 2005;23:8739–8747.
   PubMed Web of Science ®Google Scholar
• Nakayama H, Sugahara S, Tokita M, et al. Proton beam therapy for hepatocellular carcinoma: the University of Tsukuba experience. Cancer. 2009;115:5499–5506.
   PubMed Web of Science ®Google Scholar
• Fukumitsu N, Sugahara S, Nakayama H, et al. A prospective study of hypofractionated proton beam therapy for patients with hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2009;74:831–836.
   PubMed Web of Science ®Google Scholar
• Mizumoto M, Tokuuye K, Sugahara S, et al. Proton beam therapy for hepatocellular carcinoma adjacent to the porta hepatis. Int J Radiat Oncol Biol Phys. 2008;71:462–467.
   PubMed Web of Science ®Google Scholar
• Nakayama H, Sugahara S, Fukuda K, et al. Proton beam therapy for hepatocellular carcinoma located adjacent to the alimentary tract. Int J Radiat Oncol Biol Phys. 2011;80:992–995.
   PubMed Web of Science ®Google Scholar
• Kim TH, Park JW, Kim YJ, et al. Phase I dose-escalation study of proton beam therapy for inoperable hepatocellular carcinoma. Cancer Res Treat. 2015;47:34–45.
   PubMedGoogle Scholar
• Hong TS, Wo JY, Yeap BY, et al. Multi-institutional phase II study of high-dose hypofractionated proton beam therapy in patients with localized, unresectable hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol. 2016;34:460–468.
   PubMed Web of Science ®Google Scholar
• Bush DA, Kayali Z, Grove R, et al. The safety and efficacy of high-dose proton beam radiotherapy for hepatocellular carcinoma: a phase 2 prospective trial. Cancer. 2011;117:3053–3059.
   PubMed Web of Science ®Google Scholar
• Sugahara S, Oshiro Y, Nakayama H, et al. Proton beam therapy for large hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2010;76:460–466.
   PubMed Web of Science ®Google Scholar
• Hata M, Tokuuye K, Sugahara S, et al. Proton beam therapy for hepatocellular carcinoma patients with severe cirrhosis. Strahlenther Onkol. 2006;182:713–720.
   PubMed Web of Science ®Google Scholar
• Hata M, Tokuuye K, Sugahara S, et al. Proton beam therapy for aged patients with hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2007;69:805–812.
   PubMed Web of Science ®Google Scholar
• Hata M, Tokuuye K, Sugahara S, et al. Proton beam therapy for hepatocellular carcinoma with portal vein tumor thrombus. Cancer. 2005;104:794–801.
   PubMed Web of Science ®Google Scholar
• Mizumoto M, Okumura T, Hashimoto T, et al. Proton beam therapy for hepatocellular carcinoma: a comparison of three treatment protocols. Int J Radiat Oncol Biol Phys. 2011;81:1039–1045.
   PubMed Web of Science ®Google Scholar
• Fukuda K, Okumura T, Abei M, et al. Long-term outcomes of proton beam therapy in patients with previously untreated hepatocellular carcinoma. Cancer Sci. 2017;108:497–503.
   PubMed Web of Science ®Google Scholar
• Bush DA, Smith JC, Slater JD, et al. Randomized clinical trial comparing proton beam radiation therapy with transarterial chemoembolization for hepatocellular carcinoma: results of an interim analysis. Int J Radiat Oncol Biol Phys. 2016;95:477–482.
   PubMed Web of Science ®Google Scholar
• Mok KT, Wang BW, Lo GH, et al. Multimodality management of hepatocellular carcinoma larger than 10 cm. J Am Coll Surg. 2003;197:730–738.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Bustamante J, Castells A, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology. 1999;29:62–67.
   PubMed Web of Science ®Google Scholar
• Markovic S, Gadzijev E, Stabuc B, et al. Treatment options in western hepatocellular carcinoma: a prospective study of 224 patients. J Hepatol. 1998;29:650–659.
   PubMed Web of Science ®Google Scholar
• Okuda K, Ohtsuki T, Obata H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer. 1985;56:918–928.
   PubMed Web of Science ®Google Scholar
• Pawarode A, Voravud N, Sriuranpong V, et al. Natural history of untreated primary hepatocellular carcinoma: a retrospective study of 157 patients. Am J Clin Oncol. 1998;21:386–391.
   PubMed Web of Science ®Google Scholar
• Lee HS, Kim JS, Choi IJ, et al. The safety and efficacy of transcatheter arterial chemoembolization in the treatment of patients with hepatocellular carcinoma and main portal vein obstruction. A prospective controlled study. Cancer. 1997;79:2087–2094.
   PubMed Web of Science ®Google Scholar
• Kim DY, Park JW, Kim TH, et al. Risk-adapted simultaneous integrated boost-proton beam therapy (SIB-PBT) for advanced hepatocellular carcinoma with tumour vascular thrombosis. Radiother Oncol. 2017;122:122–129.
   PubMed Web of Science ®Google Scholar
• Kawashima M, Furuse J, Nishio T, et al. Phase II study of radiotherapy employing proton beam for hepatocellular carcinoma. J Clin Oncol. 2005;23:1839–1846.
   PubMed Web of Science ®Google Scholar
• Kawashima M, Kohno R, Nakachi K, et al. Dose-volume histogram analysis of the safety of proton beam therapy for unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2011;79:1479–1486.
   PubMed Web of Science ®Google Scholar
• Ohkawa A, Mizumoto M, Ishikawa H, et al. Proton beam therapy for unresectable intrahepatic cholangiocarcinoma. J Gastroenterol Hepatol. 2015;30:957–963.
   PubMed Web of Science ®Google Scholar
• Makita C, Nakamura T, Takada A, et al. Clinical outcomes and toxicity of proton beam therapy for advanced cholangiocarcinoma. Radiat Oncol. 2014;9:26.
   PubMed Web of Science ®Google Scholar
• Chiba T, Tokuuye K, Matsuzaki Y, et al. Proton beam therapy for hepatocellular carcinoma: a retrospective review of 162 patients. Clin Cancer Res. 2005;11:3799–3805.
   PubMed Web of Science ®Google Scholar
• Andolino DL, Johnson CS, Maluccio M, et al. Stereotactic body radiotherapy for primary hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2011;81:e447–453.
   PubMed Web of Science ®Google Scholar
• Nirula R, Mayberry JC. Rib fracture fixation: controversies and technical challenges. Am Surg. 2010;76:793–802.
   PubMed Web of Science ®Google Scholar
• Swanick CW, Allen PK, Tao R, et al. Incidence and predictors of chest wall toxicity after high-dose radiation therapy in 15 fractions. Pract Radiat Oncol. 2017;7:63–71.
   PubMed Web of Science ®Google Scholar
• Kanemoto A, Mizumoto M, Okumura T, et al. Dose-volume histogram analysis for risk factors of radiation-induced rib fracture after hypofractionated proton beam therapy for hepatocellular carcinoma. Acta Oncol. 2013;52:538–544.
   PubMed Web of Science ®Google Scholar
• McGowan SE, Burnet NG, Lomax AJ. Treatment planning optimisation in proton therapy. Br J Radiol. 2013;86:20120288.
   PubMed Web of Science ®Google Scholar
• Apisarnthanarax S, Vyas S, Tseng T, et al. Interfractional geometric variation in gastrointestinal organs-at-risk: implications for planning organs-at-risk and hypofractionated proton therapy. Int J Radiat Oncol Biol Phys. 2016;96:S204.
   Web of Science ®Google Scholar
• Huertas A, Baumann AS, Saunier-Kubs F, et al. Stereotactic body radiation therapy as an ablative treatment for inoperable hepatocellular carcinoma. Radiother Oncol. 2015;115:211–216.
   PubMed Web of Science ®Google Scholar
• Sanuki N, Takeda A, Oku Y, et al. Stereotactic body radiotherapy for small hepatocellular carcinoma: a retrospective outcome analysis in 185 patients. Acta Oncol. 2014;53:399–404.
   PubMed Web of Science ®Google Scholar
• Wahl DR, Stenmark MH, Tao Y, et al. Outcomes after stereotactic body radiotherapy or radiofrequency ablation for hepatocellular carcinoma. J Clin Oncol. 2016;34:452–459.
   PubMed Web of Science ®Google Scholar
• Bujold A, Massey CA, Kim JJ, et al. Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J Clin Oncol. 2013;31:1631–1639.
   PubMed Web of Science ®Google Scholar
• Lam MG, Abdelmaksoud MH, Chang DT, et al. Safety of 90Y radioembolization in patients who have undergone previous external beam radiation therapy. Int J Radiat Oncol Biol Phys. 2013;87:323–329.
   PubMed Web of Science ®Google Scholar
• Oshiro Y, Mizumoto M, Okumura T, et al. Analysis of repeated proton beam therapy for patients with hepatocellular carcinoma. Radiother Oncol. 2017;123:240–245.
   PubMed Web of Science ®Google Scholar
• Lievens Y, Pijls-Johannesma M. Health economic controversy and cost-effectiveness of proton therapy. Semin Radiat Oncol. 2013;23:134–141.
   PubMed Web of Science ®Google Scholar
• Goitein M, Jermann M. The relative costs of proton and X-ray radiation therapy. Clin Oncol (R Coll Radiol). 2003;15:S37–50.
   PubMed Web of Science ®Google Scholar
• Peeters A, Grutters JP, Pijls-Johannesma M, et al. How costly is particle therapy? Cost analysis of external beam radiotherapy with carbon-ions, protons and photons. Radiother Oncol. 2010;95:45–53.
   PubMed Web of Science ®Google Scholar
• Schulz RJ, Smith AR, Orton CG. Point/counterpoint. Proton therapy is too expensive for the minimal potential improvements in outcome claimed. Med Phys. 2007;34:1135–1138.
   PubMed Web of Science ®Google Scholar